All In Biotech

Drug Trial Radar · NCT03105102

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,336 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,336

Actual

Start

Apr 9, 2018

Primary completion

Feb 2029

Study completion Feb 2029

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Apr 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study consists of 4 sub-studies, as follows: * Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy in participants with moderately to severely active Crohn's disease (CD) who responded to intravenous risankizumab induction treatment in Study M16-006 or Study M15-991; * Sub-study 2 (Randomized, exploratory maintenance study) to evaluate the efficacy and safety of two different dosing regimens for risankizumab as maintenance therapy in participants who responded to induction treatment in Study M16-006 or Study M15-991; * Sub-study 3 (Open-label, long-term extension study) to evaluate long-term safety of risankizumab in participants who completed Sub-study 1, Sub-study 2, another AbbVie risankizumab Crohn's disease study, or participants who responded to induction treatment in Study M16-006 or Study M15-991 with no final endoscopy due to the Covid-19 pandemic. Additional objectives are to further investigate long-term efficacy and tolerability of risankizumab; * Sub-study 4 (Open-label On Body Injector (OBI) administration and long-term extension study) to evaluate patient-reported outcomes, efficacy, safety, tolerability, and pharmacokinetics of risankizumab administered via OBI in participants who are receiving maintenance treatment with risankizumab. * OL CTE to ensure uninterrupted care in accordance with local regulations until risankizumab is commercially available for participants who completed Sub-study 3, Sub-study 4.

Conditions

  • Crohn's Disease

Interventions

  • Placebo for Risankizumab SCDrug

    Placebo for Risankizumab SC Subcutaneous (SC) Injection

  • Risankizumab IVDrug

    Risankizumab IV Intravenous (IV) infusion

  • Placebo for Risankizumab IVDrug

    Placebo for Risankizumab IV Intravenous (IV) infusion

  • Risankizumab SCDrug

    Risankizumab SC Subcutaneous (SC) injection

  • Risankizumab On-Body Injector (OBI)Drug

    Subcutaneous (SC) injection; on-body injector (OBI)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sub-Study 1: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical RemissionTime frame: Week 52
  2. Sub-Study 1: Percentage of Participants With Endoscopic ResponseTime frame: Week 52
  3. Sub-Study 3: Number of Participants With Adverse EventsTime frame: Up to Week 220
  4. Sub-Study 4: Percentage of Participants With an Observer Rating of Successful Participant Self AdministrationTime frame: Up to Week 16
  5. Sub-Study 4: Percentage of Participants who had no Potential HazardsTime frame: Up to Week 16
  6. Sub-Study 4: Percentage of Participants Rating of Acceptability Using Self-Injection Assessment Questionnaire (SIAQ) at Weeks 0, 8, 16Time frame: Up to Week 16
  7. Sub-Study 4: Percentage of Participants in CDAI Clinical Remission at Week 0, 16Time frame: Up to Week 16

Locations

496 sites in 47 countries. Site status is shown where the registry gives one.

  • Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211884

    Mesa, Arizona

  • Phoenix VA Health Care System /ID# 162264

    Phoenix, Arizona

  • Banner - University Medical Center Tucson /ID# 158502

    Tucson, Arizona

  • Atria Clinical Research /ID# 164505

    Little Rock, Arkansas

  • Southern California Res. Ctr. /ID# 211991

    Coronado, California

  • Duplicate_Newport Huntington Medical Group /ID# 213035

    Huntington Beach, California

  • UC San Diego Health Systems /ID# 155555

    La Jolla, California

  • United Medical Doctors /ID# 207888

    Los Alamitos, California

  • TLC Clinical Research Inc /ID# 212719

    Los Angeles, California

  • Gastrointestinal Biosciences Clinical Trials /ID# 162657

    Los Angeles, California

  • United Medical Doctors - Murrieta /ID# 158300

    Murrieta, California

  • University of California San Francisco - Mission Bay /ID# 157127

    San Francisco, California

  • Duplicate_Cedars-Sinai Medical Center-West Hollywood /ID# 163839

    West Hollywood, California

  • Peak Gastroenterology Associates, PC /ID# 165843

    Colorado Springs, Colorado

  • Rocky Mountain Pediatric Gastroenterology /ID# 207170

    Lone Tree, Colorado

  • Duplicate_Western Connecticut Medical Group /ID# 165879

    Danbury, Connecticut

  • Brandon Premier Health Care, PA/Gulf Coast Research Group, LLC /ID# 162262

    Brandon, Florida

  • South Lake Pain Institute, Inc /ID# 162808

    Clermont, Florida

  • Universal Axon Clinical Research /ID# 165428

    Doral, Florida

  • Nature Coast Clinical Research - Inverness /ID# 159408

    Inverness, Florida

  • SIH Research Mumtaz, Inc /ID# 163083

    Kissimmee, Florida

  • Alliance Medical Research /ID# 163837

    Lighthouse PT, Florida

  • Cfagi Llc /Id# 202479

    Maitland, Florida

  • Sylvester Comprehensive Cancer Center /ID# 155007

    Miami, Florida

  • Coral Research Clinic /ID# 158456

    Miami, Florida

  • South Florida Research Ph I-IV, Inc. /ID# 161832

    Miami, Florida

  • Gastroenterology Group Naples /ID# 165204

    Naples, Florida

  • Advanced Research Institute, Inc /ID# 161966

    New Port Richey, Florida

  • Endoscopic Research, Inc. /ID# 205906

    Orlando, Florida

  • Omega Research - Orlando /ID# 171082

    Orlando, Florida

  • IMIC Inc. Medical Research /ID# 154942

    Palmetto Bay, Florida

  • Duplicate_Clinical Research of West Florida, Inc /ID# 208125

    Tampa, Florida

  • Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 205865

    Tampa, Florida

  • Atlanta Gastro Assoc /ID# 154724

    Atlanta, Georgia

  • Gastroenterology Associates of Central Georgia, LLC /ID# 154850

    Macon, Georgia

  • Duplicate_Northwestern University /ID# 158261

    Chicago, Illinois

  • The University of Chicago Medical Center /ID# 157124

    Chicago, Illinois

  • NorthShore University-Endeavor Health Evanston Hospital /ID# 158265

    Evanston, Illinois

  • Southwest Gastroenterology /ID# 164781

    Oak Lawn, Illinois

  • Cotton O'Neil Clinical Research Center, Digestive Health /ID# 154722

    Topeka, Kansas

Showing 40 of 496 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.